All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-07-29T11:02:41.000Z

Brentuximab vedotin in combination with standard chemotherapy for pediatric patients with newly diagnosed, ALK+ ALCL

Jul 29, 2021
Share:

Bookmark this article

Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma that accounts for 10–15% of all childhood lymphomas. It is characterized by pleomorphic tumor cells and strong expression of CD30. ALCL can be classified into two groups based on the expression of the ALCL kinase (ALK). ALK+ ALCL accounts for over 95% of pediatric ALCL. Although numerous treatment strategies have been investigated, approximately 30% of pediatric patients with ALCL relapse.1

Brentuximab vedotin (BV) consists of an anti-CD30 antibody conjugated to monomethyl auristatin E (MMAE); this antibody-drug conjugate has demonstrated excellent activity as a single agent in adults with ALCL and children with relapsed ALCL, though it has not been investigated in newly diagnosed pediatric patients. Therefore, the Children’s Oncology Group (COG) trial ANHL12P1 (NCT01979536) was initiated to investigate the toxicity and efficacy of BV or crizotinib in combination with standard chemotherapy (ALCL99 protocol) in children with newly diagnosed, non-localized, ALK+/CD30+ ALCL. Results of the BV arm were published by Eric Lowe and colleagues in the journal Blood and are summarized below.1  

Study design and patient characteristics1

  • This was a partially randomized, phase II trial to determine the toxicity and efficacy of the addition of BV or crizotinib to standard chemotherapy in pediatric patients (<22 years of age) with newly diagnosed, non-localized, ALK+/CD30+ ALCL.
    • Sixty-eight patients were enrolled in the BV arm between November 8, 2013, and January 20, 2017, across 52 centers.
    • The data cutoff was September 30, 2019.
    • Forty-eight patients were randomized to the BV arm and 20 patients with body surface area (BSA) <0.9 m2 were nonrandomly assigned to the BV arm, due to difficulties in dosing crizotinib in these patients.
  • The dosing schedule can be seen in Figure 1. All patients received a 5-day prophase followed by standard chemotherapy with the addition of BV.

Figure 1. Dosing schedule*

*Data from Lowe et al.1

  • Baseline characteristics can be seen in Table 1.
    • Median age at enrollment was 12 years.
    • There were slightly more males than females (63.2% vs 36.8%).
    • Extranodal sites of disease were common; 61.8% of patients had ≥1 extranodal site of disease.

Table 1. Baseline characteristics*

Characteristic

N = 68

Median age (range), years

12 (2–21)

Age group, %

              <6 years

19.1

              6–12 years

36.8

              ≥13 years

44.1

Male/female, %

63.2/36.8

Stage, %

              II

16.2

              III

70.6

              IV

13.2

Site of disease, %

              Lymph node

95.6

              Bone

23.5

              Bone marrow

13.2

              Liver

1.5

              Lung

13.2

              Skin

4.4

              Soft tissue

29.4

              Spleen

10.3

*Adapted from Lowe et al.1

Results1

Dose modifications

  • One patient did not receive BV as they were taken off the protocol at the treating physician’s discretion during prophase.
  • Three patients received a dose reduction of BV to 1.2 mg/kg due to mucositis or elevated ALT.
    • One of these patients was taken off the protocol after Cycle 3 at the treating physician’s discretion.

Toxicity

  • 67 patients were evaluable for toxicity assessment.
    • There were no toxic deaths, cases of progressive multifocal leukoencephalopathy syndrome, or cases of Grade 3/4 neuropathy.
    • Grade 3/4 toxicities occurring in more than 5% of cycles included hematologic toxicities, mucositis, and febrile neutropenia (Table 2)

Table 2. Grade 3/4 adverse events*

Adverse event, %

Grade 3
(n = 67)

Grade 4
(n = 67)

Hematologic

              Anemia

13.8

0.8

              Neutropenia

5.0

19.0

              Thrombocytopenia

5.5

8.5

              Febrile neutropenia

13.0

0.5

Nonhematologic

              Oral mucositis

5.3

0.3

              Anaphylaxis

0.3

              Appendicitis

0.3

              Catheter-related infections

0.5

              Lung infection

0.8

              Sepsis

0.3

              Skin infection

0.3

              Urinary tract infection

0.5

              Other infections and infestations

1.8

0.3

Laboratory

              ALT increase

3.8

1.0

              AST increase

2.0

0.3

              Hypokalemia

3.3

0.3

Vascular

              Thromboembolic event

0.8

ALT, alanine aminotransferase; AST, aspartate aminotransferase.
*Adapted from Lowe et al.1

Response

  • Relapse occurred in 14 patients (~20%) and were the only events contributing to event-free survival (EFS).
    • 79% of relapses occurred within 10 months of diagnosis (median time from diagnosis to relapse, 7.5 months; range, 5.5–22 months).
    • Only one patient relapsed during therapy (after the 6th chemotherapy cycle, but before off-therapy evaluation).
    • Lung involvement was the only clinical factor associated with EFS (p = 0.026).
  • Other response parameters can be seen in Table 3. The median follow-up for patients who were alive at last contact was 2.5 years (range, 1.2–5.2 years).

Table 3. Response*

Response

%

95% CI

2-year EFS

79.1

67.2–87.1%

2-year OS

97.0

88.1–99.2%

Complete response rate

              After Cycle 2

62

              After Cycle 6

97

CI, confidence interval; EFS, event-free survival; OS, overall survival.
*Data from Lowe et al.1

  • Fifty-seven patients had available baseline data for the analysis of minimal disseminated disease (MDD), which was defined as >10 normalized copy numbers of the NPM-ALK fusion transcript.
    • MDD was highly predictive of outcome and impacted the 2-year EFS (p = 0.00043) and overall survival (p = 0.041).
    • The 2-year EFS estimate was 89.0% for MDD-negative patients (n = 38) vs 52.6% for MDD-positive patients (n = 19).

Conclusions

The addition of BV to standard chemotherapy for pediatric patients with newly diagnosed, non-localized, ALK+/CD30+ ALCL prevents relapses during therapy without adding significant toxicity. This is an important result for patients with ALCL, as those that relapse during treatment tend to have worse outcomes. The study also demonstrated that MDD detection in peripheral blood can be used as a prognostic tool for EFS. However, this study was limited in that patients were spread sparsely between treatment centers so inter-laboratory differences may have influenced the results. Therefore, further studies are required to test the efficacy of BV in different subgroups of patients.

  1. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: Results of COG trial ANHL12P1. 2021;137(26):3595-3603. DOI: 10.1182/blood.2020009806

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox